Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
This article was originally published in The Pink Sheet Daily
Executive Summary
Somewhat similar to Pfizer's recent agreement with Shanghai Pharmaceuticals Holdings, the deal will focus on manufacturing and broader commercialization of medicines.